Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study
Our study suggests that nivolumab can be a reasonable option with the durable response for RR PCNSL.
Authors
- Seok Jin Kim (ORCID: https://orcid.org/0000-0002-2776-4401)
- Dok Hyun Yoon (ORCID: https://orcid.org/0000-0002-8289-3548)
- Jongheon Jung (ORCID: https://orcid.org/0000-0001-5886-0933)
- Jun Ho Yi (ORCID: https://orcid.org/0000-0003-1499-7131)
- Sang‐A Kim (ORCID: https://orcid.org/0000-0002-8529-0232)
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Bundang Hospital (KR)
- University of Ulsan (KR)
- National Cancer Center (US)
- National Cancer Center (KR)
- Chung-Ang University (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2024-08-16
- DOI
- https://doi.org/10.4143/crt.2024.531
- Citations
- 3
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.11